Parkinson Pipeline Project

The Pipeline Project Needs Your Help

What's New...

Parkinson's Insights - Perspectives from PDF

Robin Elliott, Executive Director of PDF has started a Blog.

PD Online Research, powered by Michael J. Fox Foundation - PD Online Research is a collaborative community for technical discussion and problem-solving in Parkinson’s disease science.

Pipeline Project Director Perry Cohen, Ph.D., is participating in ANSI workgroup. This task force is defining standards for inter-operable electronic medical records.

Press release

Gene Therapies for PD in clinical trials: a summary of gene therapy treatments tracked by the Parkinson Pipeline Project Database

GDNF - An Alternate Method of Delivery, by Parkinson's Med (a blog)

Parkinson's Patients Plea to Amgen: Third Anniversary, by Parkinson's Med (a blog)

Repairing the Parkinson's Pipeline, by Robin Elliott, Executive Director of the Parkinson’s Disease Foundation

Response to Robin Elliott, by Perry Cohen, Ph.D., Project Director

Terminated Experimental Treatments

Opinion: Is there an important pattern in the seemingly uninterrupted failure of drugs and biologics?
Read this Op/Ed

On the Toxicity of GDNF:
A challenge to Amgen's monkey GDNF toxicity study

Book: "Monkeys in the Middle: How One Drug Company Kept a Parkinson's Disease Breakthrough Out of Reach" by investigative journalist Nick Nelson, has just been published and is available on Amazon.

The "Access, Compassion, Care, and Ethics for Seriously Ill Patients Act"
or the Access Act (S3046 ) was introduced in the Senate in May. It is a bill to amend the Federal Food, Drug, and Cosmetic Act to create a new conditional approval system for drugs, biological products, and devices that is responsive to the needs of seriously ill patients, and for other purposes. For Details see Library of Congress, Thomas

Past What's New items have been archived on
this page.

The Parkinson Pipeline
Project is supported by
the Parkinson's Disease Foundation (PDF),
a 501(c)3 Corporation headquartered in New York City.

Tax deductible donations to the Parkinson Pipeline Project, made through this website to Donate.net, go
to the PDF designated for use by the Parkinson Pipeline Project.

FIND A CLINICAL TRIAL

What is the Pipeline Project?

The Parkinson Pipeline Project is a grassroots group of advocates whose goal is to provide the patient perspective in the treatment development process. Through education, consultation, and participation with all stakeholders - including industry and the FDA - the Parkinson Pipeline Project hopes to increase clinical trial participation and accelerate approved treatment options. New PD treatments are followed from pre-clinical development to approval in the Pd Pipeline Database found on our website. More info...

"The missing ingredient in the development of new therapies is the voice of the patient."

Project Director

Declaration of Clinical Research Rights and Responsibilities
for People With Parkinson’s

Clinical research is essential to the development of new therapies and treatments for Parkinson’s disease. Yet, due to a number of factors, including a lack of awareness and understanding of the research process, only one percent of people with Parkinson’s participate. This is far below the number needed, delaying many promising trials. Read the entire Declaration!

Parkinson's Disease Clinical Trials: Square Pegs in Round Holes?

Poster presented by the Parkinson Pipeline Project at the
2009 American Society for Experimental Neurotherapeutics (ASENT) Conference
Read the Poster Content

"Ethical Issues in Clinical Neuroscience Research: A Patient's Perspective"

Written by Parkinson Pipeline Project members
Published in Neurotherapeutic, Vol. 4, No. 3, 2007.
Read the article

To access PD Pipeline database records related to these news items - please click on

Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease Read press release

Piclozotan - New Developments in the Treatment of Motor Complications Associated with Parkinson's Therapy Read (5/09)

Update from WeMove on Rotigotine (AAN 2009), Read (5/14/09)

Commencement of Clinical Study of Cogane with Patients with Parkinson's Read press release (4/20/09)

Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial - The Six-Month Primary Efficacy Endpoint of the Study was met: Both Doses of Investigational Agent Safinamide Significantly Increased "ON" Time in Levodopa-Treated Patients With mid- to Late-Stage Parkinson's Disease - Secondary Efficacy Endpoints of the Study Analyzed to Date Were met in Both Safinamide Dose Groups Read press release (3/3/09)

Researchers Find Placebos Mimic the Effect of Active Medication in Parkinson's Disease (6/10/09) Read the full article

FDA Scraps Helsinki Declaration on Protecting Human Subjects" Read full opinion

FDA Signals High Bar for Stem Cell Treatments. Read full article and comments in Wall Street Journal Health Blog.

When Registering Trials is No Help by Merrill Goozner, from GoozNews blog, March 7 2008
Read article

Gains Come with Risks, Sometimes Personal Costs by Peggy Willocks

Profit Over Common Sense
Andy Grove Speaks to Society for Neuroscience

New data has patient advocates still asking: Why did Amgen halt its GDNF trials?
Given the overwhelmingly positive phase I trial results, and the inconclusive results of the phase II trial, the research should have been continued.

Tell Us What You Think

For archived op/eds see Op Eds / Perspectives

Your access to and use of the information contained in this web site is subject to this Terms and Conditions of Use Agreement. By accessing and using this web site, you accept this Terms and Conditions of Use Agreement.

The contents of this website and all communications with Parkinson Pipeline Project (PPP) are solely for information purposes and are not intended as medical advice. While we make every effort to assure that the information is accurate and up to date, an error may >occasionally occur. All information and materials are provided AS IS without any warranty of any kind. In no event will the PPP be held liable for any damages arising out of information contained in our website.

If any provision of this Terms and Conditions of Use Agreement is held to be unlawful, void, or unenforceable, then such provision shall be deemed severed without affecting the enforceability of all remaining provisions.